Mental health is just as important as physical health
As obesity treatment has grown more varied and accessible, a new study presented at the American Society for Metabolic and Bariatric Surgery's 2025 annual meeting asks a question medicine has long deferred: what does each path do to the mind? Analyzing five years of outcomes across more than 67,000 matched patients, researchers found that those who underwent bariatric surgery developed new psychiatric disorders — including cognitive deficits, anxiety, and substance use — at meaningfully lower rates than those taking GLP-1 medications. The findings do not diminish either approach, but they insist that weight loss and mental health are not separate stories.
- A study of 33,600 matched patient pairs reveals that bariatric surgery patients developed cognitive deficits at rates 54% lower than GLP-1 drug users over five years — a gap too large to dismiss.
- The rise of weekly GLP-1 injections as a convenient alternative to surgery has reshaped obesity treatment, but this research suggests the easier path may carry an underexamined psychiatric cost.
- Researchers used propensity score matching to control for age, sex, and existing conditions, lending the findings enough rigor to move the conversation from speculation to clinical urgency.
- Dr. Shauna Levy of Tulane University and ASMBS president Dr. Ann M. Rogers are both calling for psychiatric screening and ongoing mental health monitoring to be built into all obesity treatment programs.
- The mechanism behind the disparity — whether hormonal, surgical, behavioral, or something else — remains unknown, and researchers say closing that explanatory gap is now the critical next step.
At the American Society for Metabolic and Bariatric Surgery's 2025 annual meeting, researchers presented findings that complicate the growing enthusiasm for GLP-1 medications as a simpler alternative to surgery. Over five years, patients who underwent bariatric surgery developed new psychiatric disorders at substantially lower rates than those taking drugs like semaglutide or liraglutide — with cognitive deficits occurring 54% less frequently, anxiety disorders 18% less, and substance use disorders 17% less.
The study drew on TriNetX, a large medical records database, comparing 33,600 bariatric surgery patients with 33,600 GLP-1 users carefully matched for age, sex, and existing health conditions. The five-year follow-up window was long enough to capture meaningful psychiatric events, and the propensity score matching was designed to ensure the two groups were genuinely comparable — people who made different treatment choices, not people who were different to begin with.
Dr. Shauna Levy, bariatric surgery chief at Tulane University, argued the findings point to something beyond weight loss itself, calling for psychiatric screening and support to be embedded in both surgical and medical obesity programs. Why surgery appears more protective for mental health — whether through hormonal shifts, the nature of the intervention, or other factors — remains an open question that researchers say demands urgent investigation.
The study lands at a moment when GLP-1 drugs are widely celebrated for their effectiveness and convenience. Yet the data suggests that the less invasive option may carry a different psychological burden. Dr. Ann M. Rogers, ASMBS president, urged clinicians and patients alike to monitor mood, cognition, and substance use proactively regardless of which treatment path is chosen. The broader message is unambiguous: mental health must be treated as central to obesity care, not as an afterthought to the number on the scale.
At the American Society for Metabolic and Bariatric Surgery's 2025 annual meeting, researchers presented findings that challenge assumptions about how different obesity treatments affect mental health. Over five years, people who underwent metabolic and bariatric surgery showed substantially lower rates of new psychiatric disorders than those taking GLP-1 medications like semaglutide, liraglutide, and dulaglutide.
The protective effect was striking in its specificity. Surgical patients developed cognitive deficits at rates 54 percent lower than those on GLP-1 injections. Anxiety disorders appeared 18 percent less frequently in the surgery group, and substance use disorders 17 percent less frequently. These were not marginal differences. They represented real divergence in mental health outcomes between two major approaches to treating obesity.
The study design was rigorous enough to support these claims. Researchers pulled data from TriNetX, a large medical records database, and compared 33,600 bariatric surgery patients with 33,600 people taking GLP-1 medications. They used propensity score matching to balance the two groups—controlling for age, sex, existing health conditions, and other factors that might skew results. This meant they were comparing similar people who chose different treatments, not apples to oranges. The follow-up period stretched to five years, long enough to capture meaningful psychiatric events.
Dr. Shauna Levy, an assistant professor and bariatric surgery chief at Tulane University, emphasized that the findings point to something deeper than simple weight loss. "The data supports embedding psychiatric screening and support within both surgical and medical obesity programs," she said, noting that the psychological impact differs substantially between treatment modalities. The question of why—whether it's related to the surgery itself, hormonal changes, the intensity of the intervention, or something else entirely—remains unanswered. That gap in understanding is precisely what researchers say needs investigation next.
The findings arrive at a moment when GLP-1 drugs have become ubiquitous in obesity treatment, praised for their effectiveness and relative simplicity. A weekly injection is far less invasive than surgery. Yet this study suggests that the less invasive path may carry a different mental health burden than the more dramatic surgical intervention. Dr. Ann M. Rogers, president of the American Society for Metabolic and Bariatric Surgery, cautioned that the difference matters. "Even small differences can impact quality of life," she said, urging patients and doctors to monitor mood, cognition, and substance use proactively after starting any obesity therapy.
The implication is clear: mental health cannot be treated as secondary to weight loss. Whether someone chooses surgery or medication, psychiatric support should be woven into their care plan from the beginning. The study does not explain the mechanism behind the disparity, but it makes the case that such explanation is urgent. As obesity treatment options expand, understanding their full impact on the mind becomes as important as measuring their effect on the scale.
Citações Notáveis
The data supports embedding psychiatric screening and support within both surgical and medical obesity programs to help reduce the potential mental health burden after treatment.— Dr. Shauna Levy, Tulane University
Even small differences can impact quality of life, so patients and their doctors should be proactive about monitoring mood, cognition, and substance use after starting any obesity therapy.— Dr. Ann M. Rogers, President, ASMBS
A Conversa do Hearth Outra perspectiva sobre a história
Why would surgery protect mental health better than a medication?
That's the question the researchers couldn't answer. It could be hormonal—surgery changes gut physiology in ways that might affect mood. Or it could be psychological; the commitment and intensity of surgery might create a different mindset than a weekly injection. We don't know yet.
Does this mean GLP-1 drugs are bad for mental health?
Not necessarily. The study shows they're associated with higher rates of certain psychiatric disorders, but it doesn't prove the drug causes them. People choosing different treatments might have different baseline risks. Still, the difference was large enough that it warrants attention.
What should someone do if they're considering GLP-1 treatment?
Talk to their doctor about mental health monitoring. The study isn't saying don't take the medication—it's saying be aware, watch for changes in mood or cognition, and get support if you need it. Both treatments work for weight loss. The question is which one fits your whole life.
Is this study the final word?
No. It's a strong signal, but it's observational—it shows correlation, not causation. We need research that actually explains the mechanism. Why does surgery seem protective? That's the next frontier.